Navigation Links
Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin Capsule
Date:8/6/2008

The Trial Demonstrated the Safety and Efficacy of the ORMD 0801- Oral

Insulin Capsule

JERUSALEM, Israel, August 6 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP)(http://www.oramed.com), a developer of oral delivery systems, announced today successful results from the clinical trial of its oral insulin capsule, ORMD 0801. The trial demonstrated that the product had a good safety profile and was well tolerated and effective in lowering blood glucose levels in patients with type 2 diabetes.

The study was conducted at Hadassah University Medical Center in Jerusalem and was a continuation of the successful Phase 1B trials that Oramed completed earlier this year.

This trial was the first to expose patients with type 2 diabetes to ORMD 0801 and its primary goals were to assess the safety, tolerability and pharmcodynamic effects in these patients.

ORMD 0801 was well tolerated by all patients and had a good safety profile; no serious adverse events were encountered throughout the study. In 6 of the 9 subjects analyzed, statistically significant reductions in glucose as well as C-peptide were observed.

"We are pleased with the results from the Phase 2A trial as they showed that ORMD 0801 was effective and there were no safety issues," said Oramed's Chief Scientist, Dr. Miriam Kidron. "We look forward to our next phase of testing and taking the next steps towards making an oral insulin capsule a reality for millions of diabetics around the world."

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 clinical trials. Established in 2006, Oramed's te
'/>"/>

SOURCE Oramed Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine technology :

1. Oramed Pharmaceuticals to Hold Conference Call on August 6 to Present Results of Phase 2A Oral Insulin Capsule Clinical Trials
2. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
3. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
4. Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
5. Celator Pharmaceuticals Raises Series C Financing in Excess of $22.5 Million
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results and Provide a Clinical Program Update on August 7, 2008
7. Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer
8. Meditrina Pharmaceuticals, Inc. Opens Investigational New Drug (IND) Application for Phase IIb Clinical Trial With MPI-676 in Endometriosis
9. BioNumerik Pharmaceuticals Observes Evidence of a Survival Increase in Lung Cancer Patients Participating in Tavocept(TM) Clinical Trial
10. Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease
11. MAP Pharmaceuticals Announces Publication of MAP0004 Study in Current Medical Research and Opinion

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)... /PRNewswire/ -- On Sept. 11, 2001, thousands of...rkers came together to save as many lives as possi...Cauley was one of those 9/11 first responders. Now...n his late 30s, McCauley was diagnosed with cancer...hemotherapy treatments, leaving him confined to a ...
(Date:11/9/2009)...e/ -- AMD LASERS just announced that industry lead...pted the position of Medical Director. In his new...g research and development of new soft and hard ti...ontinuing education credits, authoring articles fo... lecturing and seminar engagements. ,, "We are ...
(Date:11/9/2009)...Newswire/ -- LifeNet Health, a leading allograft b...raft Cervical Bio-Implant (VG2C) with Preservon...prietary glycerol-based preservation solution that...ully hydrated state at ambient temperature. This e...lants, doing away with lengthy thawing and rehydra...
Breaking Medicine Technology:The SCOOTER Store Surprises 9/11 First Responder & Merrick Firefighter With Power Chair 2The SCOOTER Store Surprises 9/11 First Responder & Merrick Firefighter With Power Chair 3AMD LASERS Names Dr. James Jesse as Medical Director 2LifeNet Health Announces First Bio-Implant with New Preservation Technology 2SXC Health Solutions to present at upcoming conferences 58075 1SXC Health Solutions to present at upcoming conferences 58075 2Study Suggests a Wider Use for Statins 58073 1Study Suggests a Wider Use for Statins 58073 2Study Suggests a Wider Use for Statins 58073 3Georgia State researcher to use 241 million grant to improve computer models for fighting wildfires 10045 1Georgia State researcher to use 241 million grant to improve computer models for fighting wildfires 10045 2
...mab Cancer Trial Is Evaluating the, Anti-Tumor A...atin and Paclitaxel --...als, Inc. (Nasdaq: PPHM ) today announced that pa... trial designed to evaluate the safety,and efficac...in patients,with non-small cell lung cancer (NSCLC...
...etics,(Nasdaq: DCGN ) today announced positive to...y study of DG041, the company,s first-in-class,ant...developed as a,next-generation oral anti-platelet ... increasing bleeding risk. The prospective, random... on platelet activation and,bleeding time of DG041...
Other Medicine Technology:Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer 2Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer 3Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer 4DG041 Blocks Platelet Aggregation Through a Novel Mechanism and does not Increase Bleeding Time When Given Alone or with Plavix(TM) or Aspirin 2DG041 Blocks Platelet Aggregation Through a Novel Mechanism and does not Increase Bleeding Time When Given Alone or with Plavix(TM) or Aspirin 3DG041 Blocks Platelet Aggregation Through a Novel Mechanism and does not Increase Bleeding Time When Given Alone or with Plavix(TM) or Aspirin 4
(Date:11/9/2009)...tCall/ - Hard To Treat Diseases (HTDS.PK) www.htd...$41 billion international healthcare company, is a...r, Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.,...begin a five-year, $1 billion China initiative wit... its investment in its China R&D facility, and...
(Date:11/9/2009)...late when it comes to preventing or improving a di...ke Off Pounds Sensibly), the nonprofit weight-loss...(Vocus) November 9, 2009 -- Tomorrow may be too la...etes condition, according to TOPS Club, Inc. (Take...upport organization., , ,Diabetes is a disease in ...
(Date:11/9/2009)... positive influence of sports participation on bon...Vocus) November 9, 2009 -- As people age fractures...ch has highlighted the importance of exercise and ...However, a new study published in the November/Dec... Approach reveals that there may be significant g...
(Date:11/9/2009).../ -- Actress Mariska Hargitay and the Joyful Hea...to raise awareness about the need for domestic vio...ilding healing and wellness kits for women in cris... to each of the estimated 600 women currently bein...iolence shelters. ,, "Our goal is to shine a li...
(Date:11/9/2009)...assador ,, WHITE PLAINS, N.Y., Nov. 9 /PRNews..., was born so early and with so many underdevelope...ld survive -- or if he would ever walk, talk, see ...Dimes 2010 National Ambassador. ,, Joshua,s mo...motherhood and I was completely devastated. My hus...
Breaking Medicine News(10 mins):Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 2Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 3Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 4Health News:Diabetes Prevention Is the Best Remedy, TOPS Medical Expert Says 2Health News:Diabetes Prevention Is the Best Remedy, TOPS Medical Expert Says 3Health News:High Impact Sports Participation May Improve Bone Mineral Density in Mature Athletes 2Health News:Actress Mariska Hargitay and the Joyful Heart Foundation Join philosophy to Serve Women in Crisis Throughout Los Angeles County 2Health News:Actress Mariska Hargitay and the Joyful Heart Foundation Join philosophy to Serve Women in Crisis Throughout Los Angeles County 3Health News:Six-Year-Old Survivor Fights for Preemies Like Himself 2Health News:Six-Year-Old Survivor Fights for Preemies Like Himself 3
...to be a common condition among the senior lot in A...heir recovery process from an illness or accident...Sydneys Prince of Wales Hospital showed that almos...of stay in the hospital. Associate Profes...
...rough suppressing communication between the cells ...epsy and schizophrenia. Researchers at th...a protein that could do the trick. The SUMO protei...kling diseases such as epilepsy and schizophrenia,...
...utated with no recourse, injected stem cells could...g. Thus stem cells offer immense hope to scientis... patient. Now, scientists have explored th...mbryos, called hemangioblast cells are capable of ...
...the lesser of two evils or the better of two goods...d by just one name , is a severely disabled nine -...sability, mental disability as well renders her mi... whom they refer to as the pillow angel, on an onl...
...es not do any good to the human body, it is known.... lot may have higher blood pressure and heart rat...s hormones that strain the heart, more depression ...ally let go of things, shows a new study by psycho...
...nd psychology research both indicate that paying c...cing something else. However, a new study... that attention does not have a fixed capacity - a...psychology and psychiatry professor Richard Davids...
Other Medicine News:Health News:British Scientists Discover New Protein to Treat Epilepsy and Schizophrenia 2Health News:Human Rights Activists Sleepless In Seattle 2Health News:Brooding Could Kill, Warn Psychologists 2Health News:Meditation May Fine-Tune Control Over Attention 2
Calcitonin Assay Immunoradiometric (IRMA) Assay
...licular C-cells of the thyroid gland and is packag...itonin is to lower plasma calcium concentrations, ...creased mobilization of calcium from bone [1]. Thi...with high levels of bone remodeling (e.g. in Paget...
Calcitonin RIA Kit
...n Frequency Doubling Technology. It represents a s... combining early glaucoma detection capabilities, ...management tools., ,Like the Humphrey FDT Peri... screener with 35 second supra-threshold testing. ...
Medicine Products: